Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Therapeutic Advances in Psychopharmacology Pub Date : 2021-10-08 eCollection Date: 2021-01-01 DOI:10.1177/20451253211045870
Frank M C Besag, Michael J Vasey, Aditya N Sharma, Ivan C H Lam
{"title":"Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review.","authors":"Frank M C Besag,&nbsp;Michael J Vasey,&nbsp;Aditya N Sharma,&nbsp;Ivan C H Lam","doi":"10.1177/20451253211045870","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bipolar disorder (BD) is a cyclic mood disorder characterised by alternating episodes of mania/hypomania and depression interspersed with euthymic periods. Lamotrigine (LTG) demonstrated some mood improvement in patients treated for epilepsy, leading to clinical studies in patients with BD and its eventual introduction as maintenance therapy for the prevention of depressive relapse in euthymic patients. Most current clinical guidelines include LTG as a recommended treatment option for the maintenance phase in adult BD, consistent with its global licencing status.</p><p><strong>Aims: </strong>To review the evidence for the efficacy and safety of LTG in the treatment of all phases of BD.</p><p><strong>Methods: </strong>PubMed was searched for double-blind, randomised, placebo-controlled trials using the keywords: LTG, Lamictal, 'bipolar disorder', 'bipolar affective disorder', 'bipolar I', 'bipolar II', cyclothymia, mania, manic, depression, depressive, 'randomised controlled trial', 'randomised trial', RCT and 'placebo-controlled' and corresponding MeSH terms. Eligible articles published in English were reviewed.</p><p><strong>Results: </strong>Thirteen studies were identified. The strongest evidence supports utility in the prevention of recurrence and relapse, particularly depressive relapse, in stabilised patients. Some evidence suggests efficacy in acute bipolar depression, but findings are inconsistent. There is little or no strong evidence in support of efficacy in acute mania, unipolar depression, or rapid-cycling BD. Few controlled trials have evaluated LTG in bipolar II or in paediatric patients. Indications for safety, tolerability and patient acceptability are relatively favourable, provided there is slow dose escalation to reduce the probability of skin rash.</p><p><strong>Conclusion: </strong>On the balance of efficacy and tolerability, LTG might be considered a first-line drug for BD, except for acute manic episodes or where rapid symptom control is required. In terms of efficacy alone, however, the evidence favours other medications.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"11 ","pages":"20451253211045870"},"PeriodicalIF":3.4000,"publicationDate":"2021-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/64/10.1177_20451253211045870.PMC8504232.pdf","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253211045870","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 11

Abstract

Background: Bipolar disorder (BD) is a cyclic mood disorder characterised by alternating episodes of mania/hypomania and depression interspersed with euthymic periods. Lamotrigine (LTG) demonstrated some mood improvement in patients treated for epilepsy, leading to clinical studies in patients with BD and its eventual introduction as maintenance therapy for the prevention of depressive relapse in euthymic patients. Most current clinical guidelines include LTG as a recommended treatment option for the maintenance phase in adult BD, consistent with its global licencing status.

Aims: To review the evidence for the efficacy and safety of LTG in the treatment of all phases of BD.

Methods: PubMed was searched for double-blind, randomised, placebo-controlled trials using the keywords: LTG, Lamictal, 'bipolar disorder', 'bipolar affective disorder', 'bipolar I', 'bipolar II', cyclothymia, mania, manic, depression, depressive, 'randomised controlled trial', 'randomised trial', RCT and 'placebo-controlled' and corresponding MeSH terms. Eligible articles published in English were reviewed.

Results: Thirteen studies were identified. The strongest evidence supports utility in the prevention of recurrence and relapse, particularly depressive relapse, in stabilised patients. Some evidence suggests efficacy in acute bipolar depression, but findings are inconsistent. There is little or no strong evidence in support of efficacy in acute mania, unipolar depression, or rapid-cycling BD. Few controlled trials have evaluated LTG in bipolar II or in paediatric patients. Indications for safety, tolerability and patient acceptability are relatively favourable, provided there is slow dose escalation to reduce the probability of skin rash.

Conclusion: On the balance of efficacy and tolerability, LTG might be considered a first-line drug for BD, except for acute manic episodes or where rapid symptom control is required. In terms of efficacy alone, however, the evidence favours other medications.

Abstract Image

Abstract Image

Abstract Image

拉莫三嗪治疗双相情感障碍的有效性和安全性:一项系统综述。
背景:双相情感障碍(BD)是一种周期性的情绪障碍,其特征是躁狂/轻躁狂和抑郁交替发作,并穿插在平静期。拉莫三嗪(LTG)在癫痫治疗患者中显示出一定程度的情绪改善,这导致了对BD患者的临床研究,并最终将其作为预防心境正常患者抑郁复发的维持治疗。目前大多数临床指南都将LTG作为成人BD维持期的推荐治疗方案,这与LTG的全球许可状态一致。目的:回顾LTG治疗bd各阶段疗效和安全性的证据。方法:在PubMed检索双盲、随机、安慰剂对照试验,检索关键词为:LTG、Lamictal、“双相情感障碍”、“双相情感障碍”、“双相I型”、“双相II型”、循环精神障碍、躁狂、躁狂、抑郁、抑郁、“随机对照试验”、“随机对照试验”、“随机对照试验”、“随机对照试验”、RCT和“安慰剂对照”以及相应的MeSH术语。对已发表的符合条件的英文文章进行综述。结果:确定了13项研究。最有力的证据支持在预防复发和复发方面的效用,特别是在稳定的患者中抑郁症复发。一些证据表明对急性双相抑郁症有效,但研究结果不一致。很少或没有强有力的证据支持急性躁狂症、单极抑郁症或快速循环双相障碍的疗效。很少有对照试验评估双相II或儿科患者的LTG。安全性、耐受性和患者可接受性的适应症相对有利,前提是剂量缓慢递增以减少皮疹的可能性。结论:考虑到疗效和耐受性的平衡,除了急性躁狂发作或需要快速控制症状的情况外,LTG可能被认为是治疗双相障碍的一线药物。然而,单就疗效而言,证据更倾向于其他药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.90
自引率
2.40%
发文量
35
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信